This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Morphic Holding Past Earnings Performance

Past criteria checks 0/6

Morphic Holding's earnings have been declining at an average annual rate of -30.3%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 3% per year.

Key information

-30.3%

Earnings growth rate

18.8%

EPS growth rate

Biotechs Industry Growth	-14.6%
Revenue growth rate	-3.0%
Return on equity	-29.1%
Net Margin	n/a
Last Earnings Update	30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Morphic Holding makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:31Y Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
30 Jun 24	0	-180	47
31 Mar 24	0	-161	41
31 Dec 23	1	-152	39
30 Sep 23	7	-136	37
30 Jun 23	9	-130	35
31 Mar 23	69	-64	34
31 Dec 22	71	-59	32
30 Sep 22	74	-56	32
30 Jun 22	75	-51	31
31 Mar 22	19	-106	29
31 Dec 21	20	-96	28
30 Sep 21	16	-92	25
30 Jun 21	39	-61	23
31 Mar 21	43	-50	20
31 Dec 20	45	-45	18
30 Sep 20	39	-47	17
30 Jun 20	19	-61	15
31 Mar 20	17	-55	13
31 Dec 19	17	-43	10
30 Sep 19	21	-29	9
30 Jun 19	15	-27	7
31 Mar 19	9	-24	6
31 Dec 18	3	-24	5

Quality Earnings: 31Y is currently unprofitable.

Growing Profit Margin: 31Y is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 31Y is unprofitable, and losses have increased over the past 5 years at a rate of 30.3% per year.

Accelerating Growth: Unable to compare 31Y's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 31Y is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-0.08%).

Return on Equity

High ROE: 31Y has a negative Return on Equity (-29.08%), as it is currently unprofitable.

This company listing is no longer active

Morphic Holding Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released: US$3.59 loss per share (vs US$1.55 loss in FY 2022)

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

First quarter 2023 earnings released: US$0.90 loss per share (vs US$0.85 loss in 1Q 2022)

Full year 2022 earnings released: US$1.55 loss per share (vs US$2.67 loss in FY 2021)

Third quarter 2022 earnings released: US$0.78 loss per share (vs US$0.69 loss in 3Q 2021)

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

New major risk - Share price stability

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Full year 2023 earnings released: US$3.59 loss per share (vs US$1.55 loss in FY 2022)

Insufficient new directors

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

First quarter 2023 earnings released: US$0.90 loss per share (vs US$0.85 loss in 1Q 2022)

Full year 2022 earnings released: US$1.55 loss per share (vs US$2.67 loss in FY 2021)

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

Third quarter 2022 earnings released: US$0.78 loss per share (vs US$0.69 loss in 3Q 2021)

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Second quarter 2022 earnings released: EPS: US$0.70 (vs US$0.77 loss in 2Q 2021)

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

First quarter 2022 earnings released: US$0.85 loss per share (vs US$0.64 loss in 1Q 2021)

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Morphic Therapeutic Announces Management Appointments

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

Founder recently bought €3.6m worth of stock

Second quarter 2021 earnings released: US$0.77 loss per share (vs US$0.52 loss in 2Q 2020)

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000E Index

Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 At ECCO'21 Virtual Congress

Founder recently bought €8.7m worth of stock

Independent Director has left the company

First quarter 2021 earnings released: US$0.64 loss per share (vs US$0.56 loss in 1Q 2020)

Morphic Announces Clinical Results Update

Independent Director recently bought €59k worth of stock

Full year 2020 earnings released: US$1.47 loss per share (vs US$2.69 loss in FY 2019)

Revenue misses expectations

Morphic Holding, Inc. Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057

New 90-day high: €68.50

New 90-day high: €28.20

Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program

New 90-day high: €27.20

Morphic Holding, Inc. Appoints Martin Edwards to Serve on the Board as A Class II Director

New 90-day high: €25.60

Third quarter 2020 earnings released: EPS US$0.17

Revenue beats expectations

Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020

Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000 Value Index

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies